Skip to main content
. 2017 Aug 10;34(9):160. doi: 10.1007/s12032-017-1014-2

Fig. 2.

Fig. 2

Study sample selection (a) and cohort allocation (b). AR andrgoen receptor, mCRPC metastatic castration-resistant prostate cancer. aExcluded from the further analyses